123 related articles for article (PubMed ID: 23813855)
41. Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines.
Manetti F; Brullo C; Magnani M; Mosci F; Chelli B; Crespan E; Schenone S; Naldini A; Bruno O; Trincavelli ML; Maga G; Carraro F; Martini C; Bondavalli F; Botta M
J Med Chem; 2008 Mar; 51(5):1252-9. PubMed ID: 18257513
[TBL] [Abstract][Full Text] [Related]
42. Discovery of a diaminoquinoxaline benzenesulfonamide antagonist of HIV-1 Nef function using a yeast-based phenotypic screen.
Trible RP; Narute P; Emert-Sedlak LA; Alvarado JJ; Atkins K; Thomas L; Kodama T; Yanamala N; Korotchenko V; Day BW; Thomas G; Smithgall TE
Retrovirology; 2013 Nov; 10():135. PubMed ID: 24229420
[TBL] [Abstract][Full Text] [Related]
43. Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors.
Liu JJ; Zhang H; Sun J; Wang ZC; Yang YS; Li DD; Zhang F; Gong HB; Zhu HL
Bioorg Med Chem; 2012 Oct; 20(20):6089-96. PubMed ID: 22985957
[TBL] [Abstract][Full Text] [Related]
44. Structural modifications of 5,6-dihydroxypyrimidines with anti-HIV activity.
Guo DL; Zhang XJ; Wang RR; Zhou Y; Li Z; Xu JY; Chen KX; Zheng YT; Liu H
Bioorg Med Chem Lett; 2012 Dec; 22(23):7114-8. PubMed ID: 23099098
[TBL] [Abstract][Full Text] [Related]
45. Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
Chatain N; Ziegler P; Fahrenkamp D; Jost E; Moriggl R; Schmitz-Van de Leur H; Müller-Newen G
Oncogene; 2013 Aug; 32(31):3587-97. PubMed ID: 22926520
[TBL] [Abstract][Full Text] [Related]
46. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives containing benzodioxole as potential anticancer agents.
Wang HH; Qiu KM; Cui HE; Yang YS; Yin-Luo ; Xing M; Qiu XY; Bai LF; Zhu HL
Bioorg Med Chem; 2013 Jan; 21(2):448-55. PubMed ID: 23245802
[TBL] [Abstract][Full Text] [Related]
47. New insights into small-molecule inhibitors of Bcr-Abl.
Schenone S; Bruno O; Radi M; Botta M
Med Res Rev; 2011 Jan; 31(1):1-41. PubMed ID: 19714578
[TBL] [Abstract][Full Text] [Related]
48. Novel, selective CDK9 inhibitors for the treatment of HIV infection.
Németh G; Varga Z; Greff Z; Bencze G; Sipos A; Szántai-Kis C; Baska F; Gyuris A; Kelemenics K; Szathmáry Z; Minárovits J; Kéri G; Orfi L
Curr Med Chem; 2011; 18(3):342-58. PubMed ID: 21143121
[TBL] [Abstract][Full Text] [Related]
49. Oligomerization is required for HIV-1 Nef-induced activation of the Src family protein-tyrosine kinase, Hck.
Ye H; Choi HJ; Poe J; Smithgall TE
Biochemistry; 2004 Dec; 43(50):15775-84. PubMed ID: 15595833
[TBL] [Abstract][Full Text] [Related]
50. Bacterial expression and purification of active hematopoietic cell kinase.
Kristelly R; Qiu TW; Gunn NJ; Scanlon DB; Mulhern TD
Protein Expr Purif; 2011 Jul; 78(1):14-21. PubMed ID: 21385611
[TBL] [Abstract][Full Text] [Related]
51. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
Keller G; Schafhausen P; Brummendorf TH
Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
[TBL] [Abstract][Full Text] [Related]
52. Pyrazolo[1,5-a]pyrimidine-based macrocycles as novel HIV-1 inhibitors: a patent evaluation of WO2015123182.
Sun L; Gao P; Zhan P; Liu X
Expert Opin Ther Pat; 2016 Sep; 26(9):979-86. PubMed ID: 27398994
[TBL] [Abstract][Full Text] [Related]
53. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
54. 3D QSAR models built on structure-based alignments of Abl tyrosine kinase inhibitors.
Falchi F; Manetti F; Carraro F; Naldini A; Maga G; Crespan E; Schenone S; Bruno O; Brullo C; Botta M
ChemMedChem; 2009 Jun; 4(6):976-87. PubMed ID: 19326384
[TBL] [Abstract][Full Text] [Related]
55. Lead optimization of diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Zeng ZS; Liang YH; Feng XQ; Chen FE; Pannecouque C; Balzarini J; De Clercq E
ChemMedChem; 2010 Jun; 5(6):837-40. PubMed ID: 20333620
[No Abstract] [Full Text] [Related]
56. HIV-1 Nef perturbs the function, structure, and signaling of the Golgi through the Src kinase Hck.
Hiyoshi M; Takahashi-Makise N; Yoshidomi Y; Chutiwitoonchai N; Chihara T; Okada M; Nakamura N; Okada S; Suzu S
J Cell Physiol; 2012 Mar; 227(3):1090-7. PubMed ID: 21567396
[TBL] [Abstract][Full Text] [Related]
57. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
58. A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors.
Manetti F; Locatelli GA; Maga G; Schenone S; Modugno M; Forli S; Corelli F; Botta M
J Med Chem; 2006 Jun; 49(11):3278-86. PubMed ID: 16722646
[TBL] [Abstract][Full Text] [Related]
59. Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway.
Roversi FM; Pericole FV; Machado-Neto JA; da Silva Santos Duarte A; Longhini AL; Corrocher FA; Palodetto B; Ferro KP; Rosa RG; Baratti MO; Verjovski-Almeida S; Traina F; Molinari A; Botta M; Saad ST
Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):450-461. PubMed ID: 27840303
[TBL] [Abstract][Full Text] [Related]
60. GRID and docking analyses reveal a molecular basis for flavonoid inhibition of Src family kinase activity.
Wright B; Watson KA; McGuffin LJ; Lovegrove JA; Gibbins JM
J Nutr Biochem; 2015 Nov; 26(11):1156-65. PubMed ID: 26140983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
